162 related articles for article (PubMed ID: 38170137)
1. Use of Proton Pump Inhibitors and Risk of Fracture in Adults: A Review of Literature.
Paudel Y; Najam B; Desai HN; Illango J; Seffah KD; Kumar M; Naveen N; Pachchipulusu VK; Penumetcha SS
Cureus; 2023 Dec; 15(12):e49872. PubMed ID: 38170137
[TBL] [Abstract][Full Text] [Related]
2. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study.
Freedberg DE; Haynes K; Denburg MR; Zemel BS; Leonard MB; Abrams JA; Yang YX
Osteoporos Int; 2015 Oct; 26(10):2501-7. PubMed ID: 25986385
[TBL] [Abstract][Full Text] [Related]
3. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
van der Hoorn MMC; Tett SE; de Vries OJ; Dobson AJ; Peeters GMEEG
Bone; 2015 Dec; 81():675-682. PubMed ID: 26319499
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
Poly TN; Islam MM; Yang HC; Wu CC; Li YJ
Osteoporos Int; 2019 Jan; 30(1):103-114. PubMed ID: 30539272
[TBL] [Abstract][Full Text] [Related]
5. The relationship among proton pump inhibitors, bone disease and fracture.
Targownik LE; Leslie WD
Expert Opin Drug Saf; 2011 Nov; 10(6):901-12. PubMed ID: 21599546
[TBL] [Abstract][Full Text] [Related]
6. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
7. Fracture risk and bone mineral density reduction associated with proton pump inhibitors.
Lau YT; Ahmed NN
Pharmacotherapy; 2012 Jan; 32(1):67-79. PubMed ID: 22392829
[TBL] [Abstract][Full Text] [Related]
8. Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.
Kendler DL; Marin F; Geusens P; López-Romero P; Lespessailles E; Body JJ; Minisola S
Bone; 2020 Jan; 130():115113. PubMed ID: 31654779
[TBL] [Abstract][Full Text] [Related]
9. Proton pump inhibitors, bone and phosphocalcic metabolism.
Philippoteaux C; Paccou J; Chazard E; Cortet B
Joint Bone Spine; 2024 Mar; 91(5):105714. PubMed ID: 38458487
[TBL] [Abstract][Full Text] [Related]
10. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.
Roux C; Goldstein JL; Zhou X; Klemes A; Lindsay R
Osteoporos Int; 2012 Jan; 23(1):277-84. PubMed ID: 21365461
[TBL] [Abstract][Full Text] [Related]
11. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study.
Moberg LM; Nilsson PM; Samsioe G; Borgfeldt C
Maturitas; 2014 Aug; 78(4):310-5. PubMed ID: 24958166
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.
Park JH; Song YM; Jung JH; Han K
Bone; 2020 Jun; 135():115306. PubMed ID: 32126312
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
Lin SM; Yang SH; Liang CC; Huang HK
Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
[TBL] [Abstract][Full Text] [Related]
14. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study.
Fraser LA; Leslie WD; Targownik LE; Papaioannou A; Adachi JD;
Osteoporos Int; 2013 Apr; 24(4):1161-8. PubMed ID: 22890365
[TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.
Gray SL; LaCroix AZ; Larson J; Robbins J; Cauley JA; Manson JE; Chen Z
Arch Intern Med; 2010 May; 170(9):765-71. PubMed ID: 20458083
[TBL] [Abstract][Full Text] [Related]
16. Acid-suppressive medications and risk of bone loss and fracture in older adults.
Yu EW; Blackwell T; Ensrud KE; Hillier TA; Lane NE; Orwoll E; Bauer DC
Calcif Tissue Int; 2008 Oct; 83(4):251-9. PubMed ID: 18813868
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies.
Ngamruengphong S; Leontiadis GI; Radhi S; Dentino A; Nugent K
Am J Gastroenterol; 2011 Jul; 106(7):1209-18; quiz 1219. PubMed ID: 21483462
[TBL] [Abstract][Full Text] [Related]
18. Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study.
Abtahi S; Driessen JHM; Burden AM; Souverein PC; van den Bergh JP; van Staa TP; Boonen A; de Vries F
Ann Rheum Dis; 2021 Apr; 80(4):423-431. PubMed ID: 33310727
[TBL] [Abstract][Full Text] [Related]
19. Osteoporosis or fracture risk associated with thiazolidinedione and proton pump inhibitor co-administration in patients with type 2 diabetes mellitus.
Ock M; Lee S; Kim H
J Clin Pharm Ther; 2022 Jul; 47(7):1028-1035. PubMed ID: 35257383
[TBL] [Abstract][Full Text] [Related]
20. Lower Trabecular Bone Score is Associated With the Use of Proton Pump Inhibitors.
Shin YH; Gong HS; Baek GH
J Clin Densitom; 2019; 22(2):236-242. PubMed ID: 30100220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
